Page last updated: 2024-10-15

alpha-hydroxyglutarate and Leukemia, Myeloid, Acute

alpha-hydroxyglutarate has been researched along with Leukemia, Myeloid, Acute in 35 studies

2-hydroxyglutarate : A dicarboxylic acid anion obtained by deprotonation of at least one of the carboxy groups of 2-hydroxyglutaric acid.
2-hydroxyglutaric acid : A 2-hydroxydicarboxylic acid that is glutaric acid in which one hydrogen alpha- to a carboxylic acid group is substituted by a hydroxy group.

Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.

Research Excerpts

ExcerptRelevanceReference
"We studied whether 2HG measurements in acute myeloid leukemia (AML) patients correlate with IDH mutations, and whether diagnostic or remission 2HG measurements predict survival."2.78Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. ( Abdel-Wahab, O; Agresta, S; Carroll, M; DiNardo, CD; Fernandez, HF; Lazarus, HM; Levine, RL; Litzow, MR; Loren, AW; Luger, SM; Margolis, DJ; Paietta, E; Patel, JP; Perl, AE; Propert, KJ; Rowe, JM; Straley, KS; Sun, Z; Tallman, MS; Yen, K, 2013)
"Glutaminase (GLS) is a mitochondrial enzyme that catalyzes the conversion of Gln to glutamate."1.43Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. ( Baran, N; Cai, T; Chan, SM; Davis, RE; DiNardo, C; Flores, ER; Gonzalez, D; Haferlach, T; Jacamo, R; Konoplev, S; Konopleva, M; Li, W; Lodi, A; Ma, H; Majeti, R; Matre, P; Qi, Y; Samudio, I; Schimmer, AD; Su, X; Sweeney, SR; Tiziani, S; Velez, J; Wang, T, 2016)
" Inhibition of glutaminase by allosteric GLS inhibitor bis-2-(5-phenylacetamido-1, 2, 4-thiadiazol-2-yl) ethyl sulfide or by novel, potent, orally bioavailable GLS inhibitor CB-839 reduced intracellular glutamate levels and inhibited growth of AML cells."1.43Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. ( Baran, N; Cai, T; Chan, SM; Davis, RE; DiNardo, C; Flores, ER; Gonzalez, D; Haferlach, T; Jacamo, R; Konoplev, S; Konopleva, M; Li, W; Lodi, A; Ma, H; Majeti, R; Matre, P; Qi, Y; Samudio, I; Schimmer, AD; Su, X; Sweeney, SR; Tiziani, S; Velez, J; Wang, T, 2016)
"We investigated whether, in acute myeloid leukemia (AML), serum 2-HG would predict the presence of IDH1/2 mutations at diagnosis and provide a marker of minimal residual disease (MRD)."1.40Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. ( Auger, N; Barouki, R; Bennaceur-Griscelli, A; Bernard, OA; Berthon, C; Caillot, D; Chachaty, E; Courtier, MH; de Botton, S; Dombret, H; Forget, S; Griscelli, F; Janin, M; Koscielny, S; Leclercq, E; Micol, JB; Mylonas, E; Ottolenghi, C; Pautas, C; Penard-Lacronique, V; Preudhomme, C; Quivoron, C; Rabier, D; Renneville, A; Saada, V; Scourzic, L; Solary, E, 2014)
"Acute leukemias are clonal disorders of hematopoiesis wherein a leukemic stem cell (LSC) acquires mutations that confer the capacity for unlimited self-renewal, impaired hematopoietic differentiation, and enhanced proliferation to the leukemic clone."1.36Metabolism and the leukemic stem cell. ( Abdel-Wahab, O; Levine, RL, 2010)

Research

Studies (35)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's32 (91.43)24.3611
2020's3 (8.57)2.80

Authors

AuthorsStudies
Lyu, J1
Liu, Y1
Gong, L1
Chen, M1
Madanat, YF1
Zhang, Y1
Cai, F1
Gu, Z1
Cao, H1
Kaphle, P1
Kim, YJ1
Kalkan, FN1
Stephens, H1
Dickerson, KE1
Ni, M1
Chen, W1
Patel, P1
Mims, AS1
Borate, U1
Burd, A1
Cai, SF1
Yin, CC1
You, MJ1
Chung, SS1
Collins, RH1
DeBerardinis, RJ1
Liu, X1
Xu, J1
Thomas, D2
Wu, M1
Nakauchi, Y1
Zheng, M1
Thompson-Peach, CAL1
Lim, K1
Landberg, N1
Köhnke, T1
Robinson, N1
Kaur, S1
Kutyna, M1
Stafford, M1
Hiwase, D1
Reinisch, A1
Peltz, G1
Majeti, R3
Gunn, K1
Myllykoski, M1
Cao, JZ1
Ahmed, M1
Huang, B1
Rouaisnel, B1
Diplas, BH1
Levitt, MM1
Looper, R1
Doench, JG1
Ligon, KL1
Kornblum, HI1
McBrayer, SK1
Yan, H1
Duy, C1
Godley, LA2
Koivunen, P1
Losman, JA1
Dang, L4
Su, SM4
Showalter, MR1
Hatakeyama, J1
Cajka, T1
VanderVorst, K1
Carraway, KL1
Fiehn, O1
Jones, PM1
Boriack, R1
Struys, EA4
Rakheja, D1
Montalban-Bravo, G1
DiNardo, CD2
Lin, P1
Luo, Y1
Zhu, S1
Maggio, D1
Yang, H3
Hu, C1
Wang, J1
Zhang, H1
Ren, Y1
Zhou, X1
Mei, C1
Ma, L1
Xu, W1
Ye, L1
Zhuang, Z1
Jin, J2
Tong, H1
Bories, PN1
Nakib, S1
Cynober, L1
Alary, AS1
Coude, MM1
Chevillon, F1
Tamburini, J1
Birsen, R1
Kosmider, O1
Bouscary, D1
Brunner, AM1
Neuberg, DS1
Wander, SA1
Sadrzadeh, H1
Ballen, KK1
Amrein, PC1
Attar, E1
Hobbs, GS1
Chen, YB1
Perry, A1
Connolly, C1
Joseph, C1
Burke, M1
Ramos, A1
Galinsky, I1
Yen, K4
Straley, K3
Agresta, S3
Adamia, S1
Borger, DR1
Iafrate, A1
Graubert, TA1
Stone, RM1
Fathi, AT1
Wang, F1
Travins, J1
DeLaBarre, B1
Penard-Lacronique, V3
Schalm, S1
Hansen, E1
Kernytsky, A1
Liu, W1
Gliser, C1
Gross, S2
Artin, E1
Saada, V3
Mylonas, E2
Quivoron, C3
Popovici-Muller, J1
Saunders, JO1
Salituro, FG1
Yan, S1
Murray, S1
Wei, W1
Gao, Y1
Dorsch, M1
Schenkein, DP2
Biller, SA1
de Botton, S3
Yen, KE1
Propert, KJ1
Loren, AW1
Paietta, E1
Sun, Z1
Levine, RL4
Straley, KS1
Patel, JP1
Abdel-Wahab, O4
Perl, AE2
Litzow, MR1
Rowe, JM1
Lazarus, HM1
Fernandez, HF1
Margolis, DJ1
Tallman, MS1
Luger, SM1
Carroll, M2
Guilhamon, P1
Eskandarpour, M1
Halai, D1
Wilson, GA1
Feber, A1
Teschendorff, AE1
Gomez, V1
Hergovich, A1
Tirabosco, R1
Fernanda Amary, M1
Baumhoer, D1
Jundt, G1
Ross, MT1
Flanagan, AM1
Beck, S1
Wang, JH1
Chen, WL1
Li, JM1
Wu, SF1
Chen, TL1
Zhu, YM1
Zhang, WN1
Li, Y2
Qiu, YP1
Zhao, AH1
Mi, JQ1
Wang, YG1
Ma, QL1
Huang, H1
Wu, DP1
Wang, QR1
Yan, XJ1
Yan, JS1
Li, JY1
Wang, S1
Huang, XJ1
Wang, BS1
Jia, W1
Shen, Y1
Chen, Z1
Chen, SJ1
Janin, M1
Micol, JB1
Renneville, A1
Koscielny, S1
Scourzic, L1
Forget, S1
Pautas, C1
Caillot, D1
Preudhomme, C1
Dombret, H1
Berthon, C1
Barouki, R1
Rabier, D1
Auger, N1
Griscelli, F1
Chachaty, E1
Leclercq, E1
Courtier, MH1
Bennaceur-Griscelli, A1
Solary, E1
Bernard, OA1
Ottolenghi, C1
Wiseman, DH2
Small, HF1
Wilks, DP2
Waddell, ID1
Dennis, MW2
Ogilvie, DJ1
Somervaille, TC2
Chan, SM2
Corces-Zimmerman, MR1
Xavy, S1
Rastogi, S1
Hong, WJ1
Zhao, F1
Medeiros, BC2
Tyvoll, DA1
Clark, CI1
Jansen, EE2
Salomons, GS1
Balss, J2
Thiede, C2
Bochtler, T2
Okun, JG3
Saadati, M1
Benner, A1
Pusch, S3
Ehninger, G1
Schaich, M1
Ho, AD3
von Deimling, A4
Krämer, A4
Heilig, CE1
Attar, EC1
Chaturvedi, A2
Araujo Cruz, MM1
Jyotsana, N1
Sharma, A2
Goparaju, R2
Schwarzer, A1
Görlich, K1
Schottmann, R1
Rohde, C1
Müller-Tidow, C1
Geffers, R2
Göhring, G1
Ganser, A2
Thol, F2
Heuser, M2
Poinsignon, V1
Mercier, L1
Nakabayashi, K1
David, MD1
Lalli, A1
Broutin, S2
Paci, A2
Kingsbury, JM1
Shamaprasad, N1
Billmyre, RB1
Heitman, J1
Cardenas, ME1
Chen, JY1
Lai, YS1
Tsai, HJ1
Kuo, CC1
Yen, BL1
Yeh, SP1
Sun, HS1
Hung, WC1
Matre, P1
Velez, J1
Jacamo, R1
Qi, Y1
Su, X2
Cai, T1
Lodi, A1
Sweeney, SR1
Ma, H1
Davis, RE1
Baran, N1
Haferlach, T1
Flores, ER1
Gonzalez, D1
Konoplev, S1
Samudio, I1
DiNardo, C1
Schimmer, AD1
Li, W1
Wang, T1
Tiziani, S1
Konopleva, M1
Lemonnier, F1
Cairns, RA2
Inoue, S1
Li, WY1
Dupuy, A1
Martin, N1
Fataccioli, V1
Pelletier, R1
Wakeham, A1
Snow, BE1
de Leval, L1
Pujals, A1
Haioun, C1
Tobin, ER1
Narayanaswamy, R1
Jin, S2
Gaulard, P1
Mak, TW2
Herbst, L1
Klett, L1
Stichel, D1
Kaulfuss, S1
Panknin, O1
Zimmermann, K1
Toschi, L1
Neuhaus, R1
Haegebarth, A1
Rehwinkel, H1
Hess-Stumpp, H1
Bauser, M1
Bakkali, A1
Araujo-Cruz, MM1
Gabdoulline, R1
Rippe, K1
Maxmen, A1
Minden, MD1
Driggers, EM1
Bittinger, MA1
Jang, HG1
Sasaki, M1
Fantin, VR2
Ward, PS1
Patel, J1
Wise, DR1
Bennett, BD1
Coller, HA1
Cross, JR1
Hedvat, CV1
Rabinowitz, JD1
Sharp, KA1
Thompson, CB1
Sellner, L1
Capper, D1
Meyer, J1
Langhans, CD2
Hartog, CM1
Pfeifer, H1
Serve, H1
Bhagwat, N1
Pollyea, DA1
Kohrt, HE1
Zhang, B1
Zehnder, J1
Schenkein, D1
Fantin, V1
Vasanthakumar, A1
Levine, R1
Beck, AC1
Herold-Mende, C1
Buckel, W1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prevalence, Correlation With Other Mutant Genes and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia. The European IDH Research Alliance[NCT04369287]654 participants (Anticipated)Observational2016-01-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

4 reviews available for alpha-hydroxyglutarate and Leukemia, Myeloid, Acute

ArticleYear
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
    Annual review of biochemistry, 2017, 06-20, Volume: 86

    Topics: Acetamides; Antineoplastic Agents; Benzeneacetamides; Benzimidazoles; Biomarkers, Tumor; Drug Discov

2017
The role of IDH mutations in acute myeloid leukemia.
    Future oncology (London, England), 2018, Volume: 14, Issue:10

    Topics: Antimetabolites, Antineoplastic; Enzyme Inhibitors; Epigenesis, Genetic; Glutarates; Humans; Isocitr

2018
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.
    Nature communications, 2013, Volume: 4

    Topics: Bile Duct Neoplasms; Bone Neoplasms; Central Nervous System Neoplasms; Cholangiocarcinoma; Chondrosa

2013
IDH mutations in cancer and progress toward development of targeted therapeutics.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:4

    Topics: Carcinogenesis; Clinical Trials as Topic; Enzyme Inhibitors; Glutarates; Humans; Isocitrate Dehydrog

2016

Trials

3 trials available for alpha-hydroxyglutarate and Leukemia, Myeloid, Acute

ArticleYear
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.
    Blood, 2013, Jun-13, Volume: 121, Issue:24

    Topics: Adolescent; Adult; DNA Mutational Analysis; Female; Follow-Up Studies; Glutarates; Humans; Isocitrat

2013
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.
    Proceedings of the National Academy of Sciences of the United States of America, 2013, Oct-15, Volume: 110, Issue:42

    Topics: China; Disease-Free Survival; DNA Methylation; Female; Gene Expression Regulation, Leukemic; Glutara

2013
Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.
    Leukemia, 2016, Volume: 30, Issue:4

    Topics: Adolescent; Adult; Biomarkers, Tumor; Cytogenetic Analysis; Female; Follow-Up Studies; Glutarates; H

2016

Other Studies

28 other studies available for alpha-hydroxyglutarate and Leukemia, Myeloid, Acute

ArticleYear
Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance.
    Cancer discovery, 2023, 01-09, Volume: 13, Issue:1

    Topics: Amino Acids; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; NADP

2023
Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability.
    Cancer discovery, 2023, 02-06, Volume: 13, Issue:2

    Topics: Enzyme Inhibitors; Glutarates; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation

2023
(R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.
    Cancer discovery, 2023, 06-02, Volume: 13, Issue:6

    Topics: Cell Transformation, Neoplastic; DNA Methylation; Glioma; Glutarates; Histone Demethylases; Histones

2023
Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    eLife, 2017, 06-27, Volume: 6

    Topics: Biotransformation; Glutarates; Humans; Isocitrate Dehydrogenase; Ketoglutaric Acids; Leukemia, Myelo

2017
Measurement of Oncometabolites D-2-Hydroxyglutaric Acid and L-2-Hydroxyglutaric Acid.
    Methods in molecular biology (Clifton, N.J.), 2017, Volume: 1633

    Topics: Biomarkers, Tumor; Chromatography, Liquid; Glutarates; Humans; Leukemia, Myeloid, Acute; Stereoisome

2017
Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes.
    Journal of cancer research and clinical oncology, 2018, Volume: 144, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Cohort Studies; Female;

2018
Establishing assay-specific 97.5th percentile upper reference limit for serum D-2-hydroxyglutarate for the management of patients with acute myeloid leukemia.
    Clinical chemistry and laboratory medicine, 2019, 03-26, Volume: 57, Issue:4

    Topics: Blood Chemical Analysis; Glutarates; Humans; Leukemia, Myeloid, Acute

2019
Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
    Cancer, 2019, 02-15, Volume: 125, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; F

2019
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
    Science (New York, N.Y.), 2013, May-03, Volume: 340, Issue:6132

    Topics: Allosteric Site; Antineoplastic Agents; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Cell

2013
Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-01, Volume: 32, Issue:4

    Topics: Adult; Aged; Area Under Curve; Biomarkers, Tumor; Female; France; Glutarates; Humans; Isocitrate Deh

2014
Elevated plasma 2-hydroxyglutarate in acute myeloid leukaemia: association with the IDH1 SNP rs11554137 and severe renal impairment.
    British journal of haematology, 2014, Volume: 166, Issue:1

    Topics: Acute Kidney Injury; Biomarkers, Tumor; Glutarates; Humans; Isocitrate Dehydrogenase; Leukemia, Myel

2014
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.
    Nature medicine, 2015, Volume: 21, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm

2015
Direct comparison of quantitative digital PCR and 2-hydroxyglutarate enantiomeric ratio for IDH mutant allele frequency assessment in myeloid malignancy.
    Leukemia, 2015, Volume: 29, Issue:12

    Topics: Gene Frequency; Glutarates; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Po

2015
Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate.
    Leukemia, 2016, Volume: 30, Issue:8

    Topics: Animals; Clone Cells; Glutarates; Heterografts; Homeodomain Proteins; Humans; Isocitrate Dehydrogena

2016
Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2016, Jun-01, Volume: 1022

    Topics: Biomarkers, Tumor; Cell Line, Tumor; Chromatography, Liquid; Glutarates; Humans; Isocitrate Dehydrog

2016
Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability.
    Human molecular genetics, 2016, 08-15, Volume: 25, Issue:16

    Topics: Aldehyde Dehydrogenase; Alleles; Cell Line, Tumor; DNA, Mitochondrial; Glioma; Glutarates; Humans; I

2016
The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells.
    Scientific reports, 2016, 08-31, Volume: 6

    Topics: Complement C5a; Gene Expression Regulation, Leukemic; Glutarates; Humans; Interleukin-6; Interleukin

2016
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
    Oncotarget, 2016, Nov-29, Volume: 7, Issue:48

    Topics: Antineoplastic Agents; Apoptosis; Benzeneacetamides; Cell Differentiation; Cell Proliferation; Energ

2016
The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development.
    Proceedings of the National Academy of Sciences of the United States of America, 2016, 12-27, Volume: 113, Issue:52

    Topics: Animals; Biomarkers, Tumor; Flow Cytometry; Gene Expression Regulation, Neoplastic; Genotype; Glutar

2016
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
    Leukemia, 2017, Volume: 31, Issue:10

    Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; DNA Methylation

2017
Cancers converge at 2-HG.
    The Journal of experimental medicine, 2010, Feb-15, Volume: 207, Issue:2

    Topics: Brain Neoplasms; Glutarates; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; R

2010
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
    The Journal of experimental medicine, 2010, Feb-15, Volume: 207, Issue:2

    Topics: Catalysis; Glutarates; Humans; Isocitrate Dehydrogenase; Ketoglutaric Acids; Leukemia, Myeloid, Acut

2010
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Cancer cell, 2010, Mar-16, Volume: 17, Issue:3

    Topics: Cell Proliferation; Glutarates; Humans; Isocitrate Dehydrogenase; Isocitrates; Ketoglutaric Acids; L

2010
Metabolism and the leukemic stem cell.
    The Journal of experimental medicine, 2010, Apr-12, Volume: 207, Issue:4

    Topics: Animals; Cholecalciferol; Glutarates; Hematopoiesis; Hematopoietic Stem Cells; Humans; Hypoxia-Induc

2010
Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations.
    European journal of haematology, 2010, Volume: 85, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Female; Glutarates; Humans; Isocitrate Dehydrogenase; Leukemia, Myel

2010
Metabolic syndromes and malignant transformation: where the twain shall meet.
    Science translational medicine, 2010, Oct-20, Volume: 2, Issue:54

    Topics: Cell Transformation, Neoplastic; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Leukemia, Mye

2010
2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:2

    Topics: 5-Methylcytosine; Aged; Aged, 80 and over; Female; Glutarates; Humans; Isocitrate Dehydrogenase; Leu

2013
Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
    Acta neuropathologica, 2012, Volume: 124, Issue:6

    Topics: Alcohol Oxidoreductases; Biomarkers, Tumor; Enzyme Assays; Glutarates; Humans; Isocitrate Dehydrogen

2012